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A B S T R A C T   
Background: High mannose has previously associated with insulin resistance and cardiovascular disease (CVD). 
Our objective is to establish whether mannose is associated with anatomical evidence of coronary artery disease 
(CAD). 
Methods: Plasma mannose concentrations were measured by liquid chromatography/tandem mass spectrometry 
in a discovery cohort (n = 513) and a validation cohort (n = 221) of carefully phenotyped individuals. In both 
cohorts CAD was quantitated using state-of-the-art imaging techniques (coronary computed coronary tomog-
raphy angiography (CCTA), invasive coronary angiography and optical coherence tomography). Information on 
subsequent CVD events/death was collected. Associations of mannose with angiographic variables and bio-
markers were tested using univariate and multivariate regression models. Survival analysis was performed using 
the Kaplan-Meier estimator. 
Results: Mannose was related to indices of CAD and features of plaque vulnerability. In the discovery cohort, 
mannose was a marker of quantity and quality of CCTA-proven CAD and subjects with a mannose level in the top 
quartile had a significantly higher risk of CVD events/death (p = 3.6e-5). In the validation cohort, mannose was 
significantly associated with fibrous cap thickness < 65 μm (odds ratio = 1.32 per each 10 μmol/L mannose 
change [95% confidence interval, 1.05–1.65]) and was an independent predictor of death (hazard ratio for 
mannose≥vs < 84.6 μmol/L: 4.0(95%CI, 1.4–11.3), p = 0.006). 
Conclusion: The current data add novel evidence that high mannose is a signature of CAD with a vulnerable 
plaque phenotype, consistently across measures of severity of vessel involvement and independent of the 
traditional correlates of CVD, and that it is an independent predictor of incident adverse outcomes.   
Abbreviations: AUC, area under the curve; CAD, coronary artery disease; CCTA, computed tomography angiography; CVD, cardiovascular disease; FFR, fractional 
flow reserve; GDP-mannose, guanosine-diphospho-mannose; GCK, glucokinase; GMPPA/B, GDP-mannose pyrophosphorylases; HDL, high density lipoprotein; HK, 
hexokinase; HPLC-MS-MS, liquid chromatography and tandem mass spectrometry; hsCRP, High-sensitivity C-reactive protein; hs-TnT, High-sensitivity cardiac 
troponin T; IQR, interquartile range; MPI, Mannose-6 phosphate isomerase; MinFCT, Minimal fibrous cap thickness; OCT, optical coherence tomography; OR, odds 
ratio; PFK, phosphofructokinase; PMM 1, phosphomannose mutase 1; ROC, receiver operating characteristics; SD, standard deviation; T2D, type 2 diabetes. 
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1. Introduction 
Previous work – using cell-specific analysis of genome-scale meta-
bolic models, transcriptional regulatory networks, and protein-protein 
interaction networks – identified elevated circulating mannose con-
centrations as a novel marker of insulin resistance [1]. More recently, 
studies using the euglycaemic hyperinsulinaemic clamp technique to 
measure whole-body insulin sensitivity provided direct evidence that 
plasma mannose – quantitated by liquid chromatography and tandem 
mass spectrometry (HPLC-MS-MS) – is insulin regulatable and closely 
tracks in vivo insulin resistance [2]. Moreover, in epidemiological co-
horts higher plasma mannose concentrations have been associated not 
only with insulin resistance but also with risk of developing diabetes, 
diabetic kidney disease, and cardiovascular disease (CVD) [3]. The 
mechanisms underlying these associations have not been explored. In 
particular, it is not clear whether mannose is related to CVD only 
because it marks insulin resistance or because of some intrinsic biolog-
ical property. Preliminary to this inquiry is to establish whether circu-
lating mannose concentrations are indeed associated with anatomical 
evidence of extent and kind of atherosclerotic lesion characteristics of 
the coronary vasculature. 
To address this question, the present study measured plasma 
mannose concentrations in two large datasets, a discovery cohort and an 
external validation cohort, in whom coronary atherosclerosis was 
quantitated using state-of-the-art imaging techniques in carefully phe-
notyped groups of individuals. 
2. Materials and methods 
2.1. Subjects and protocols 
2.1.1. Discovery cohort (n = 513) 
CAPIRE (ClinicalTrials.gov Identifier: NCT02157662) is a multi-
centre, prospective, observational study aimed at identifying new 
mechanisms promoting or protecting against coronary athero-
thrombosis; in its longitudinal phase, subjects have been followed for 
five years. Details of the study have been reported [4]. Briefly, the study 
enrolled subjects 45 to 75 years of age (64 with type 2 diabetes (T2D)), 
without previous clinical manifestations of coronary artery disease 
(CAD) including acute myocardial infarction, unstable angina, chronic 
stable angina, previous percutaneous or surgical coronary revascular-
isation and heart failure, who underwent a 64-slice coronary computed 
tomography angiography (CCTA) because of suspected CAD. The main 
indications for CCTA were (a) uninterpretable, equivocal, or contra-
indicated functional stress test (44% of patients), (b) new-onset chest 
pain syndrome at low-intermediate pre-test likelihood of CAD (25% of 
patients), and (c) other heart disorders, documented previously or 
identified at CCTA, such as dilated or obstructive cardiomyopathy, atrial 
fibrillation, myocarditis, and inflammatory vascular disease; (d) docu-
mented peripheral vascular disease (stroke, transient ischaemic attack, 
claudication, revascularisation); and (e) active inflammatory or 
neoplastic disease (31% of patients in the last three categories 
altogether). 
Patients with T2D were further selected to be eligible for the CCTA 
procedure, i.e., if they were in good clinical condition and stable meta-
bolic control. Exclusion criteria were: (a) CCTA not meeting the quality 
control criteria; (b) previous cardiovascular events (myocardial infarc-
tion, stable or unstable angina, percutaneous or surgical coronary 
revascularisation, heart failure), both clinically evident and confirmed 
by clinical and conventional diagnostics; (c) other previous heart dis-
orders documented or identified at CCTA, such as dilated cardiomyop-
athy (regardless of aetiology), obstructive hypertrophic 
cardiomyopathy, atrial fibrillation, myocarditis, and inflammatory 
vascular disease; (d) previous documented acute or chronic peripheral 
vascular disease (stroke, transient ischaemic attack, previous revascu-
larisation); (e) claudication at rest or at low-grade effort); and (f) active 
inflammatory or neoplastic disease. 
At follow-up, the occurrence of cardiac death, acute coronary syn-
drome (defined as both ST-segment elevation myocardial infarction and 
unstable angina or non–ST-segment elevation myocardial infarction) 
and non-urgent revascularisation was recorded. 
2.1.2. Validation Cohort (n = 221) 
The Aachen OCT-cohort includes patients (130 with T2D) referred to 
the Cardiology Department of the University Hospital of the RWTH 
Aachen for planned coronary angiography due to suspected chronic 
coronary syndrome. Chronic coronary syndrome was defined as stable 
symptoms in the last 6 weeks; in case of multivessel disease, identifi-
cation of the target lesion(s) relied on stress imaging and/or fractional 
flow reserve (FFR). Further inclusion criteria were age > 30 years and 
written informed consent to the study protocol. Exclusion criteria 
included haemodynamic or rhythmic instability, acute or chronic renal 
insufficiency (serum creatinine level > 1.5 mg/dL), systemic acute or 
chronic infections, pregnancy, and anti-inflammatory medications such 
as steroids. Extensive medical history recording concomitant cardio-
vascular risk factors and relevant pharmacotherapy was available for all 
patients [5]. Of the 221 patients undergoing coronary angiography, 134 
(61%) underwent pre-interventional optical coherence tomography 
(OCT) in order to assess stenosis and plaque morphology [6]. The reason 
for not performing OCT was absence of occlusive coronary artery disease 
in 59 cases, multivessel disease with indication for coronary artery 
bypass graft in 12 cases, totally occluded and/or severely tortuous and/ 
or calcified lesions impeding the safe passage of the OCT catheter in 
eight cases. In further eight cases, reason for not performing OCT was 
represented by other exclusion criteria (among them, left main coronary 
artery stenosis, graft stenosis and in-stent restenosis). OCT images were 
acquired using a Frequency-Domain-OCT C7XR system and the Drag-
onFly catheter (St. Jude Medical Systems; Lightlab Imaging, Inc., 
Westford, Massachusetts, USA) [5]. Complete blood removal was ob-
tained through the injection of 14 mL iodixanol at a flow rate of 4 mL/s 
in the guiding catheter. The image was acquired with an automated pull- 
back at a rate of 20 mm/s. Two independent and blinded observers with 
expertise in OCT performed the plaque analysis. The analysis was car-
ried out frame by frame in 0.4 mm intervals using St. Jude’s proprietary 
software, throughout the entire lesion. The intraclass correlation co-
efficients for intraobserver and interobserver agreements were 0.979 
and 0.893 for calcium arc, 0.989 and 0.902 for calcium area and 0.949 
and 0.927 for percent area stenosis. According to consensus [6], fibrous 
cap thickness could only be assessed in lipid plaques. 
A standardised follow-up was performed reporting cause of death, 
myocardial infarction and/or emergent revascularisation. 
2.2. Analytical methods 
In all subjects, a peripheral venous blood sample was obtained under 
fasting conditions (i.e., in the morning after an overnight, 10–12-h fast) 
between 7 a.m. and 8 a.m. on the day of coronary angiography. EDTA- 
plasma samples were immediately put on ice, processed according to 
standard operating procedures and subsequently frozen at − 80 ◦C. All 
biomarkers were measured in a central laboratory, in a single batch, by 
personnel blinded to the patient characteristics. Serum creatinine, 
HbA1c and lipids were measured by standard, automated laboratory 
methods. High-sensitivity C-reactive protein (hsCRP) was measured 
with an automatic immunoturbidimetric method (Beckman-Coulter, 
Galway, Ireland). High-sensitivity cardiac troponin T (hs-TnT) was 
measured on an automated platform (ECLIA Cobas e411; Roche Di-
agnostics, Rotkreutz, Switzerland). 
Plasma mannose concentrations were measured by an HPLC-MS-MS 
method developed and validated in the Pisa Metabolism laboratory [7]. 
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2.3. Ethics 
Both studies comply with the Declaration of Helsinki on ethical 
principles for medical research involving human subjects and were 
approved by research ethics boards at each site. All participants pro-
vided written informed consent. 
2.4. Statistical analysis 
Continuous variables are presented as mean ± standard deviation 
(SD), variables with a skewed distribution (by the Shapiro-Wilk test) are 
given as median and interquartile range [IQR]. Continuous variables 
with a normal distribution were compared using ANCOVA, variables 
with a skewed distribution were compared by Kruskal-Wallis tests for 
independent samples and logarithmically transformed for use in 
ANOVA. Proportions were compared using a χ2 or Fisher exact test, as 
appropriate. The population of the validation cohort was subdivided 
into tertiles of plasma mannose concentrations. Univariate associations 
between mannose levels and clinical characteristics and biomarkers 
were performed. Associations of plasma mannose concentrations with 
CCTA and angiographic variables were tested using univariate and 
multivariate regression models and logistic regressions. Adjustments 
included those covariates that resulted significantly associated with 
plasma mannose concentrations, by Spearman correlation coefficient in 
the discovery cohort and by ANOVA according to tertiles of plasma 
mannose concentrations in the validation cohort. 
Survival analysis was carried out using the Kaplan-Meier estimator. 
To determine the diagnostic efficiency and the optimal cut-off value of 
plasma mannose in predicting mortality in the discovery cohort, we 
performed time-dependent receiver operating characteristics (ROC)- 
analysis using the R-package “timeROC” [8]; for this analysis we used a 
Kaplan-Meier estimator of the censoring distribution. Diagnostic effi-
ciency was classified as previously described [9]. We then subdivided 
the study population based on the optimal cut-off value derived from the 
ROC analysis and performed Kaplan-Meier survival analysis. Cox 
regression was used to analyse the impact of plasma mannose tertiles on 
survival. 
Statistical analyses were performed with SPSS (v 26.0, IBM Corp., 
Armonk, NY, USA) and R (v 4.0.0, The R Project) software. Statistical 
significance was awarded for p < 0.05. 
3. Results 
3.1. Discovery cohort 
Based on CCTA, the CAPIRE subjects were grouped into CAD− (clean 
coronaries, n = 340) and CAD+ (diffuse coronary atherosclerosis with or 
without coronary stenosis, n = 173). Participants in the CAD+ category 
were more often men, older and heavier than subjects in the CAD−
category; most clinical and metabolic parameters were different be-
tween the two groups, as expected (Supplementary Table 1). In the 
entire cohort, plasma mannose concentrations showed a skewed distri-
bution, with a median of 60 μmol/L and an IQR of 23 μmol/L; levels in 
CAD+ subjects were significantly higher than in CAD− subjects (68 [29] 
vs 56 [20] μmol/L) (Fig. 1a). In univariate analysis, several anthropo-
metric and metabolic factors were significantly associated with plasma 
mannose (Supplementary Table 2). Using these variables as covariates in 
a multiple regression model, plasma mannose concentrations were still 
significantly associated with the presence of CAD (p = 0.0061). In a 
multivariate logistic model of presence of CAD with the same covariates, 
the odds ratio (OR) for 1 SD plasma mannose concentrations (= 22 
μmol/L) was 1.51 [95% CI: 1.07–2.15], with an area-under-ROC of 
0.833. By including pharmacologic treatments (use of angiotensin con-
verting enzyme inhibitors or angiotensin receptor blockers, statin, 
aspirin, and diuretics), the OR for plasma mannose was 1.45 [95% CI, 
1.01–2.11], with an area-under-ROC of 0.858. 
3.1.1. Association between mannose and CCTA features 
Plasma mannose concentrations were directly related to several 
indices of coronary artery anatomy at CCTA (Table 1), including total 
plaque volume, the segment stenosis score (or overall plaque extent), the 
segment involvement score (or number of segments with at least one 
plaque irrespective of degree of stenosis), and total Leaman score 
(Fig. 1b). 
3.1.2. Association between mannose and outcomes 
Over a follow up of 60 [26] months, there were 74 first hospital 
admissions for CVD and 8 deaths. Using this outcome, subjects with a 
plasma mannose level in the top 25% of the distribution did significantly 
worse than the remainder of the cohort (Fig. 1c). 
3.2. Validation cohort 
In the whole cohort, median plasma mannose concentrations were 
92 [46] μmol/L. Mannose levels trended to be higher in patients with 
CAD vs those without CAD (100 ± 35 vs 87 ± 28 μmol/L, p = 0.070). The 
tertiles of plasma mannose concentrations were: tertile 1: <77 μmol/L; 
tertile 2: 77–100 μmol/L; tertile 3: ≥100 μmol/L. As reported in Sup-
plementary Table 3, across increasing plasma mannose levels patients 
were older and heavier and had a higher prevalence of diabetes and use 
of ß-blockers, lower levels of high density lipoprotein (HDL)-cholesterol, 
and higher levels of hsCRP; angiographic evidence of CAD also was 
higher. By multivariate logistic analysis of the data in Supplementary 
Table 3, presence of CAD was predicted by male sex (OR = 3.00 [95% 
CI:1.39–6.44]), age (OR = 1.04 [95%CI:1.00–1.09 per year]) and serum 
HDL-cholesterol (OR = 0.68 [95%CI:0.52–0.90 for 10 mg/dL]), while 
plasma mannose levels fell just short of full statistical significance (OR 
= 1.13 [95%CI: 0.99–1.28 for 10 μmol/L], p = 0.072). 
3.2.1. Plaque vulnerability by OCT 
The association of plasma mannose with features of plaque vulner-
ability was analysed by subdividing the 134 patients who received pre- 
interventional OCT into tertiles of plasma mannose concentrations 
(Table 2). Minimal fibrous cap thickness (MinFCT) in lipid plaques was 
significantly smaller across tertiles of plasma mannose; furthermore, 
patients in the highest tertile of plasma mannose presented more thin- 
capped fibroatheromas and trended to present more macrophage accu-
mulations than patients in the lower tertiles. An example of plaque 
morphology analysis with fibrous cap thickness is shown in Supple-
mentary Fig. 1. By univariate logistic analysis, the presence of a fibrous 
cap thickness < 65 μm was significantly associated with plasma 
mannose levels (OR = 1.32 [95%CI:1.05–1.65 for 10 μmol/L]), presence 
of diabetes being the only other univariate predictor (OR = 7.82 [95% 
CI:1.55–2.87]). The reciprocal curvilinear association between plasma 
mannose and MinFCT is shown in Supplementary Fig. 2. 
3.2.2. Association between mannose and outcomes 
We next tested whether the association between plasma mannose 
level and OCT-based plaque vulnerability translated into a worse 
prognosis. Follow-up data were available for 198 (90%) of the included 
patients, median follow-up time was 56 months (range 47–65 months). 
First, we performed a Kaplan-Meier analysis to assess the association 
between plasma mannose tertiles and death from any cause (29 events). 
Higher plasma mannose was associated with a higher all-cause mortality 
(Fig. 2a). The hazard ratio for the comparison of tertile 3 with tertile 1 is 
5.2 [95%CI:1.5–17.8, p = 0.014]. We then performed a time-dependent 
ROC analysis in order to gauge the diagnostic efficiency of plasma 
mannose level in predicting death at a follow-up time of 60 months. A 
satisfactory efficiency (area under the curve AUC = 0.748) was evident 
at an optimal cut-off value of 84.6 μmol/L (sensitivity: 88%; specificity: 
56%) (Supplementary Fig. 3). By subdividing the cohort according to 
this cut-off, we obtained a clear separation of the Kaplan-Meier curves 
(Fig. 2b). 
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4. Discussion 
The main findings of the present study are that plasma mannose 
concentrations are associated with the presence of CAD and with a more 
vulnerable plaque phenotype, and that mannose is an independent 
predictor of incident CV events and death. 
In the discovery cohort, plasma mannose behaved not only as a 
strong surrogate for insulin resistance but also as a consistent marker of 
quantity and quality of CCTA-proven coronary atherosclerosis. Notably, 
in the latter capacity plasma mannose was superior to both plasma 
troponin-T and hsCRP levels. Moreover, baseline mannose concentra-
tions were an independent predictor of incident CV deaths and CVD 
hospitalisations. The validation cohort included older and more obese 
participants with a chronic coronary syndrome; their plasma mannose 
levels were significantly higher than those of the discovery cohort, also 
on account of the strong association of mannose with age, body mass 
index, and cardiovascular risk factors. 
Coronary lesions have the potential to rupture and cause acute cor-
onary syndromes. Recently, pathology studies and investigations using 
intravascular imaging have identified several morphological features of 
coronary plaques that are prone to rupture. Among these features, a 
pivotal role is played by the thickness of the fibrous cap overlying the 
necrotic lipid core, which may be effectively assessed in vivo using OCT 
[5]. Specifically, a lower MinFCT is consistently associated with a higher 
incidence of acute coronary syndromes [10,11]. In the present study, we 
extend the current knowledge by showing that higher plasma mannose 
levels are associated with a lower MinFCT and trended to have more 
macrophage accumulation, suggesting a more vulnerable plaque 
Fig. 1. Discovery cohort – (a) Box plot of plasma mannose concentrations in 
subjects with (CAD+) or without (CAD− ) coronary artery disease. (b) Inde-
pendent association of plasma mannose concentrations with Leaman score; the 
fit (full line) and its 95% confidence interval (dotted lines) are leverage after 
adjustment for sex, age, BMI, presence of diabetes, cigarettes/day, plasma 
glucose and serum HbA1c levels. (c) Kaplan-Meier plot of first hospital admis-
sion for cardiovascular causes comparing patient with “high mannose” (top 
25% of the distribution) and “low mannose” (the other three quartiles); dotted 
lines are 95% confidence intervals of the fit; p value is by log rank. 
Legend: CAD = coronary artery disease. 
Table 1 
Univariate (rho) and multivariate (partial r) associations of plasma mannose 
levels with high-risk CCTA features in the discovery cohort.   
rho* p partial r* p* 
Segment Stenosis Score (1–16) 0.31 <0.0001 0.13 0.0036 
Segment Involvement Score (1–16) 0.29 <0.0001 0.13 0.0040 
Plaque total volume (mm3) 0.28 <0.0001 0.10 0.0210 
Leaman score (units) 0.28 <0.0001 0.14 0.0016 
Remodelling Index, n (%) 0.27 <0.0001 0.16 0.0023  
* Adjusted for sex, age, BMI, presence of diabetes, cigarettes/day, plasma 
glucose and serum HbA1c levels. 
Table 2 
Features of plaque vulnerability in OCT by tertiles of plasma mannose in the 
validation cohort.   
Tertile 1 Tertile 2 Tertile 3 p* 
(N = 40) (N = 52) (N = 42) 
Minimal FCT (μm) 105 ± 33 89 ± 25 76 ± 30 0.022 
Mean FCT (μm) 143 [19] 118 [36] 116 [36] Ns 
Mean Lipid Arc (degrees) 142 ± 47 142 ± 53 136 ± 51 Ns 
Lipid Volume Index (mm) 505 ± 409 501 ± 394 592 ± 463 Ns 
Presence of TCFA (n, %) 2 (5) 6 (11) 14 (33) 0.019 
Presence of microcalcification 
(n, %) 4 (10) 13 (25) 5 (12) Ns 







Presence of macrophages (n, %) 12 (30) 25 (48) 20 (48) Ns 
Macrophage Volume Index 
(†mm) 0 [36] 2 [42] 18 [56] Ns 
Entries are mean ± standard deviation or median [interquartile range]. 
FCT = fibrous cap thickness; Ns: non-significant; OCT = optical coherence to-
mography; TCFA = thin-capped fibroatheroma. 
* p by ANOVA for continuous variables with normal distribution; Kruskal- 
Wallis test for continuous variables with skewed distribution; Fisher’s exact 
test for dichotomic variables. 
† Entries are mean ± SD or median [interquartile range]. 
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phenotype. Finally, in our cohort the association between plasma 
mannose levels and plaque vulnerability translated into a worse prog-
nosis, despite the relatively small numbers. Altogether, our findings 
support that mannose may be a useful biomarker in detecting patients 
with higher risk for CAD, vulnerable plaques and cardiovascular events. 
Clinically, this may prompt toward a more aggressive management of 
patients with higher mannose levels, for instance with high-dose statins, 
which have been shown to have plaque-stabilising properties [12]. 
4.1. Biological plausibility 
Importantly, the association of mannose with coronary atheroscle-
rosis is of special significance because of its biological plausibility. 
Mannose is a C2-epimer of glucose, which circulates at concentra-
tions ~1/100th those of glucose and enters many cell types by facili-
tated diffusion [13]. Once taken up into organs, phosphorylated (by 
hexokinase 1/2, HK) and isomerised (by mannose-6 phosphate isom-
erase MPI) to fructose-6-phosphate, mannose is channelled through 
glycolysis or gluconeogenesis just like incoming glucose. Cytosolic 
mannose-6-phosphate can also be funnelled toward glycan (especially 
N-glycan) synthesis following conversion to mannose-1-phosphate – a 
reaction catalysed by phosphomannose mutase 1 (PMM1) – and con-
version of mannose-1-phosphate into guanosine-diphospho-mannose 
(GDP-mannose) by GDP-mannose pyrophosphorylases (GMPPA/B). As 
mannose has a much higher glycosylation affinity than glucose, GDP- 
mannose-derived glycans are avidly attached to proteins in a non- 
enzymatic, covalent manner. Thus, the relative partitioning of 
cytosolic mannose-6-phosphate through glycolysis vs N-glycan synthesis 
depends on the ratio of MPI to PMM1 activity. Physiologically, MPI- 
catalysed mannose utilisation greatly exceeds N-glycan synthesis [14]; 
however, glycans also derive from the lysosomal catabolism of mis-
folded proteins, mainly in the liver [15]. Mannose generated through 
this pathway escapes the hexokinase step and is exported to the blood-
stream as free mannose [16]. Thus, higher circulating mannose con-
centrations may result from (a) reduced uptake, (b) increased 
conversion of glucose, or (c) enhanced degradation of glycoproteins (or 
combinations thereof). 
In obese, insulin resistant individuals [1] (Supplementary Fig. 4), 
hepatic glucose utilisation is increased due to higher activities of 
glucokinase (GCK) and phosphofructokinase (PFK), whereby glycolysis, 
gluconeogenesis, and glycogen and lipid synthesis are enhanced. In 
contrast, mannose phosphorylation is reduced, so that mannose builds 
up in the cytoplasm and regurgitates into the plasma. This likely ac-
counts for the close association of plasma mannose with plasma glucose 
concentrations (r = 0.51, p < 0.0001 in our discovery cohort) and with 
clamp-based insulin resistance [2]. Both PMM1 and GMPP activities are 
increased in the liver of obese, insulin resistant subjects; as a conse-
quence, traffic through the N-glycan path is augmented, by increased 
glycoprotein synthesis, glycoprotein degradation or both. 
N-glycosylation controls protein folding and, through this process, 
the physicochemical properties of many membrane and secreted pro-
teins, including lipoproteins, cadherins, and plexins. Moreover, high 
mannose-type oligosaccharides linked to N-acetylglucosamine – a 
molecule that has been associated with insulin resistance and diabetic 
complications [17–20] – serve as the recognition marker that mediates 
enzyme uptake by various cell types and targeting to lysosomes [21]. 
Protein misfolding is crucially involved in immune modulation and 
atherogenesis [14,15]. Thus, high plasma mannose not only marks 
metabolic insulin resistance but may also track abnormal post- 
translational protein modification in the endoplasmic reticulum. 
Increased glycosylation is likely to be a previously unrecognised 
mechanism through which insulin resistance promotes atherosclerosis 
with or without hyperglycaemia [22–24]. 
4.2. Limitations 
Some limitations should be taken into account. First of all, plaque 
features and burden were assessed by different techniques in the dis-
covery and in the validation cohort. Although mannose concentrations 
resulted associated with well-established features of vulnerable plaque 
phenotypes in both, if anything further supporting our findings, this 
important difference between the two cohorts should be kept in mind. 
Likewise, the validation cohort included patients that can be considered 
at a somewhat higher risk of CAD compared with the discovery cohort, 
and although this serves the scope of the present investigation, residual 
confounding due to the diversity of patients’ characteristics in the two 
cohorts cannot be ruled out. Finally, the present findings support the 
described biological plausibility of mannose being a biomarker of high- 
risk coronary atherosclerosis, but further evidence is needed to confirm 
its role in clinical prediction models. In particular, in individuals with 
diabetes the exact impact of different glucose-lowering medications on 
circulating plasma mannose levels is unknown. 
5. Conclusion 
The current data add novel evidence that high circulating mannose is 
a signature of coronary atherosclerosis that is consistent across measures 
of severity of vessel involvement and independent of the canonical 
correlates of CVD. In addition, despite the small number of cardiovas-
cular outcomes, baseline mannose also had some predictive power for 
incident clinical events, confirming the observations of larger epidemi-
ological surveys obtained with the use of untargeted metabolomics [3]. 
In the perspective of personalized medicine, plasma mannose 
Fig. 2. Validation cohort - (top) Kaplan-Meier survival curves by tertiles of 
plasma mannose. (bottom) Kaplan-Meier survival curves by optimal cut-off of 
plasma mannose concentrations. 
Legend: CI = confidence interval; HR = hazard ratio. 
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concentrations could be used for screening and risk prediction of pa-
tients at high cardiovascular risk, providing further information when 
added to established risk markers. 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.ijcard.2021.11.038. 
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[23] C. Wittenbecher, T. Štambuk, O. Kuxhaus, N. Rudman, F. Vučković, J. Štambuk, 
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